• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DCAF11 通过亲电蛋白水解靶向嵌合体支持靶向蛋白降解。

DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.

机构信息

The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.

Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.

出版信息

J Am Chem Soc. 2021 Apr 7;143(13):5141-5149. doi: 10.1021/jacs.1c00990. Epub 2021 Mar 30.

DOI:10.1021/jacs.1c00990
PMID:33783207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8309050/
Abstract

Ligand-induced protein degradation has emerged as a compelling approach to promote the targeted elimination of proteins from cells by directing these proteins to the ubiquitin-proteasome machinery. So far, only a limited number of E3 ligases have been found to support ligand-induced protein degradation, reflecting a dearth of E3-binding compounds for proteolysis-targeting chimera (PROTAC) design. Here, we describe a functional screening strategy performed with a focused library of candidate electrophilic PROTACs to discover bifunctional compounds that degrade proteins in human cells by covalently engaging E3 ligases. Mechanistic studies revealed that the electrophilic PROTACs act through modifying specific cysteines in DCAF11, a poorly characterized E3 ligase substrate adaptor. We further show that DCAF11-directed electrophilic PROTACs can degrade multiple endogenous proteins, including FBKP12 and the androgen receptor, in human prostate cancer cells. Our findings designate DCAF11 as an E3 ligase capable of supporting ligand-induced protein degradation via electrophilic PROTACs.

摘要

配体诱导的蛋白质降解已成为一种引人注目的方法,可以通过将这些蛋白质定向到泛素蛋白酶体机制来促进细胞中蛋白质的靶向消除。到目前为止,仅发现少数 E3 连接酶能够支持配体诱导的蛋白质降解,这反映了用于蛋白水解靶向嵌合体(PROTAC)设计的 E3 结合化合物的缺乏。在这里,我们描述了一种使用候选亲电子 PROTAC 的重点文库进行的功能筛选策略,以发现通过共价结合 E3 连接酶降解人细胞中蛋白质的双功能化合物。机制研究表明,亲电子 PROTAC 通过修饰 DCAF11 中的特定半胱氨酸起作用,DCAF11 是一种 poorly characterized E3 连接酶底物衔接子。我们进一步表明,DCAF11 定向亲电子 PROTAC 可以降解人前列腺癌细胞中的多种内源性蛋白质,包括 FBKP12 和雄激素受体。我们的研究结果将 DCAF11 指定为一种 E3 连接酶,能够通过亲电子 PROTAC 支持配体诱导的蛋白质降解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/ac548c76cd4d/nihms-1720332-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/696c6fb3ab68/nihms-1720332-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/7b0139581a6c/nihms-1720332-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/0268279627fe/nihms-1720332-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/6faceab3ffa2/nihms-1720332-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/ac548c76cd4d/nihms-1720332-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/696c6fb3ab68/nihms-1720332-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/7b0139581a6c/nihms-1720332-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/0268279627fe/nihms-1720332-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/6faceab3ffa2/nihms-1720332-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/8309050/ac548c76cd4d/nihms-1720332-f0005.jpg

相似文献

1
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.DCAF11 通过亲电蛋白水解靶向嵌合体支持靶向蛋白降解。
J Am Chem Soc. 2021 Apr 7;143(13):5141-5149. doi: 10.1021/jacs.1c00990. Epub 2021 Mar 30.
2
Proteolysis-targeting chimeras (PROTACs) in cancer therapy.蛋白水解靶向嵌合体(PROTACs)在癌症治疗中的应用。
Mol Cancer. 2022 Apr 11;21(1):99. doi: 10.1186/s12943-021-01434-3.
3
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.E3 连接酶配体用于 PROTACs:它们是如何被发现的,以及如何发现新的配体。
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
4
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.PROteolysis TArgeting Chimeras (PROTACs) 作为新兴的抗癌治疗药物。
Oncogene. 2020 Jun;39(26):4909-4924. doi: 10.1038/s41388-020-1336-y. Epub 2020 May 31.
5
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16.通过结合 DCAF16 降解核蛋白的亲电 PROTAC 分子。
Nat Chem Biol. 2019 Jul;15(7):737-746. doi: 10.1038/s41589-019-0279-5. Epub 2019 Jun 17.
6
Synthesis and biological evaluation of niclosamide PROTACs.尼氯硝唑类蛋白水解靶向嵌合体的合成与生物评价。
Bioorg Med Chem Lett. 2022 Sep 15;72:128870. doi: 10.1016/j.bmcl.2022.128870. Epub 2022 Jun 27.
7
Discovery of E3 Ligase Ligands for Target Protein Degradation.E3 连接酶配体用于靶蛋白降解的发现。
Molecules. 2022 Oct 2;27(19):6515. doi: 10.3390/molecules27196515.
8
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.通过利用弱结合亲和力 VHL E3 连接酶配体发现高效雄激素受体(AR)的 PROTAC 降解剂。
J Med Chem. 2019 Dec 26;62(24):11218-11231. doi: 10.1021/acs.jmedchem.9b01393. Epub 2019 Dec 5.
9
Targeted protein degradation via intramolecular bivalent glues.通过分子内双价胶实现靶向蛋白降解。
Nature. 2024 Mar;627(8002):204-211. doi: 10.1038/s41586-024-07089-6. Epub 2024 Feb 21.
10
Targeted Protein Degradation through E2 Recruitment.通过 E2 招募实现靶向蛋白降解。
ACS Chem Biol. 2023 Apr 21;18(4):897-904. doi: 10.1021/acschembio.3c00040. Epub 2023 Mar 20.

引用本文的文献

1
DCAF16-Based Covalent Degradative Handles for the Modular Design of Degraders.基于DCAF16的共价降解手柄用于降解剂的模块化设计。
ACS Cent Sci. 2025 Jun 26;11(7):1207-1217. doi: 10.1021/acscentsci.5c00959. eCollection 2025 Jul 23.
2
Advancing Design Strategy of PROTACs for Cancer Therapy.用于癌症治疗的PROTACs的先进设计策略
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
3
Identification of Actionable Targeted Protein Degradation Effector Sites through Site-Specific Ligand Incorporation-Induced Proximity (SLIP).

本文引用的文献

1
Dcaf11 activates Zscan4-mediated alternative telomere lengthening in early embryos and embryonic stem cells.Dcaf11 激活 Zscan4 介导的早期胚胎和胚胎干细胞中的替代性端粒延长。
Cell Stem Cell. 2021 Apr 1;28(4):732-747.e9. doi: 10.1016/j.stem.2020.11.018. Epub 2020 Dec 23.
2
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.E3 连接酶配体用于 PROTACs:它们是如何被发现的,以及如何发现新的配体。
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
3
Bardoxolone conjugation enables targeted protein degradation of BRD4.
通过位点特异性配体掺入诱导邻近效应(SLIP)鉴定可操作的靶向蛋白质降解效应位点。
J Am Chem Soc. 2025 Jun 25;147(25):21549-21559. doi: 10.1021/jacs.5c01420. Epub 2025 Jun 10.
4
Discovery and optimisation of a covalent ligand for TRIM25 and its application to targeted protein ubiquitination.TRIM25共价配体的发现与优化及其在靶向蛋白质泛素化中的应用
Chem Sci. 2025 May 12. doi: 10.1039/d5sc01540e.
5
Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel-Lindau Tumor Suppressor Protein (VHL).发现一系列与冯·希佩尔-林道肿瘤抑制蛋白(VHL)的半胱氨酸77结合的共价配体。
ACS Med Chem Lett. 2025 Mar 19;16(4):693-699. doi: 10.1021/acsmedchemlett.4c00582. eCollection 2025 Apr 10.
6
Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells.雄激素非依赖性前列腺癌细胞中AR和AR-V7的共价去稳定降解剂
bioRxiv. 2025 Feb 16:2025.02.12.637117. doi: 10.1101/2025.02.12.637117.
7
Identification of actionable targeted protein degradation effector sites through Site-specific Ligand Incorporation-induced Proximity (SLIP).通过位点特异性配体掺入诱导邻近效应(SLIP)鉴定可操作的靶向蛋白质降解效应位点。
bioRxiv. 2025 Feb 4:2025.02.04.636303. doi: 10.1101/2025.02.04.636303.
8
Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan-Degrader.用一种DDB1和CUL4相关因子11(DCAF11)招募剂取代 Cereblon配体,可将一种选择性组蛋白去乙酰化酶6 PROTAC转化为一种泛降解剂。
ChemMedChem. 2025 May 19;20(10):e202500035. doi: 10.1002/cmdc.202500035. Epub 2025 Mar 24.
9
Harnessing the FBXW7 Somatic Mutant R465C for Targeted Protein Degradation.利用FBXW7体细胞突变体R465C进行靶向蛋白降解。
J Am Chem Soc. 2025 Feb 19;147(7):6108-6115. doi: 10.1021/jacs.4c17331. Epub 2025 Feb 6.
10
Discovery of DCAF16 Binders for Targeted Protein Degradation.用于靶向蛋白质降解的DCAF16结合剂的发现。
ACS Chem Biol. 2025 Feb 21;20(2):479-488. doi: 10.1021/acschembio.4c00799. Epub 2025 Jan 30.
巴多索隆缀合能够实现 BRD4 的靶向蛋白降解。
Sci Rep. 2020 Sep 23;10(1):15543. doi: 10.1038/s41598-020-72491-9.
4
An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells.原发性人 T 细胞中亲电半胱氨酸相互作用的活性导向图谱。
Cell. 2020 Aug 20;182(4):1009-1026.e29. doi: 10.1016/j.cell.2020.07.001. Epub 2020 Jul 29.
5
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.靶向蛋白降解作为研究工具和药理学模式的关键评估。
Trends Pharmacol Sci. 2020 May;41(5):305-317. doi: 10.1016/j.tips.2020.02.006. Epub 2020 Mar 26.
6
Quantitative Proteomics of the Cancer Cell Line Encyclopedia.癌症细胞系百科全书的定量蛋白质组学。
Cell. 2020 Jan 23;180(2):387-402.e16. doi: 10.1016/j.cell.2019.12.023.
7
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.通过利用弱结合亲和力 VHL E3 连接酶配体发现高效雄激素受体(AR)的 PROTAC 降解剂。
J Med Chem. 2019 Dec 26;62(24):11218-11231. doi: 10.1021/acs.jmedchem.9b01393. Epub 2019 Dec 5.
8
Targeted protein degradation: expanding the toolbox.靶向蛋白降解:拓展工具盒。
Nat Rev Drug Discov. 2019 Dec;18(12):949-963. doi: 10.1038/s41573-019-0047-y. Epub 2019 Oct 30.
9
Development of targeted protein degradation therapeutics.靶向蛋白降解治疗药物的研发。
Nat Chem Biol. 2019 Oct;15(10):937-944. doi: 10.1038/s41589-019-0362-y. Epub 2019 Sep 16.
10
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation.利用抗癌天然产物印苦楝素进行靶向蛋白降解。
Nat Chem Biol. 2019 Jul;15(7):747-755. doi: 10.1038/s41589-019-0304-8. Epub 2019 Jun 17.